MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Xencor Inc

Fermé

SecteurSoins de santé

8.96 -1.1

Résumé

Variation du prix de l'action

24h

Actuel

Min

8.89

Max

9.27

Chiffres clés

By Trading Economics

Revenu

5.5M

-49M

Ventes

-37M

33M

Marge bénéficiaire

-148.576

Employés

250

EBITDA

-21M

-37M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+196.47% upside

Dividendes

By Dow Jones

Prochains Résultats

1 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-382M

630M

Ouverture précédente

10.06

Clôture précédente

8.96

Sentiment de l'Actualité

By Acuity

50%

50%

169 / 376 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Strong Bearish Evidence

Xencor Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

17 juil. 2025, 23:34 UTC

Acquisitions, Fusions, Rachats

FTC Reopens Consent Orders for Proposed Acquisitions from Exxon Mobil, Chevron

17 juil. 2025, 21:14 UTC

Acquisitions, Fusions, Rachats

Basel Medical Group Puts $1 Billion Bitcoin Purchase on Hold

17 juil. 2025, 21:04 UTC

Principaux Mouvements du Marché
Acquisitions, Fusions, Rachats

Norfolk Southern Shares Rise on WSJ Report of Union Pacific Acquisition Interest

17 juil. 2025, 23:43 UTC

Market Talk

Gold Edges Higher on Possible Position Adjustments -- Market Talk

17 juil. 2025, 23:42 UTC

Market Talk

Nikkei May Rise on Signs of U.S. Econ Strength -- Market Talk

17 juil. 2025, 22:47 UTC

Acquisitions, Fusions, Rachats

FTC: Maintaining Restrictions for Former Pioneer CEO Scott Sheffield Would Damage FTC's Credibility

17 juil. 2025, 22:46 UTC

Acquisitions, Fusions, Rachats

Potential Rail Merger Could Prompt Berkshire Hathaway to Bid for CSX -- Barrons.com

17 juil. 2025, 22:46 UTC

Acquisitions, Fusions, Rachats

FTC Also Says Exxon Order Disregarded Guidelines and Precedent

17 juil. 2025, 22:43 UTC

Acquisitions, Fusions, Rachats

FTC: Maintaining Restrictions on John Hess's Employment Would 'Damage the FTC's Credibility'

17 juil. 2025, 22:43 UTC

Acquisitions, Fusions, Rachats

FTC: Chevron Order Disregarded FTC Merger Guidelines and Decades of Precedent

17 juil. 2025, 22:40 UTC

Acquisitions, Fusions, Rachats

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17 juil. 2025, 22:40 UTC

Acquisitions, Fusions, Rachats

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17 juil. 2025, 22:30 UTC

Market Talk
Résultats

Netflix Sticks to Its Playbook as Competitive Landscape Changes -- Market Talk

17 juil. 2025, 22:20 UTC

Market Talk
Résultats

Global Equities Roundup: Market Talk

17 juil. 2025, 22:20 UTC

Market Talk
Résultats

Netflix Focusing Resources on TV Viewers It Hasn't Yet Captured -- Market Talk

17 juil. 2025, 22:04 UTC

Market Talk
Résultats

Netflix Redesign Done to Match Current Capabilities -- Market Talk

17 juil. 2025, 22:03 UTC

Acquisitions, Fusions, Rachats

China Threatens to Block Panama Ports Deal Unless Its Shipping Giant Is Part of It -- 2nd Update

17 juil. 2025, 21:58 UTC

Market Talk
Résultats

Netflix Internal Data Doesn't Indicate Weaker Consumer Sentiment -- Market Talk

17 juil. 2025, 21:57 UTC

Résultats

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17 juil. 2025, 21:47 UTC

Résultats

Netflix Raises Revenue, Margin Forecasts After Strong Second Quarter -- Update

17 juil. 2025, 21:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 juil. 2025, 21:45 UTC

Market Talk

Crypto Bills Welcomed by Venture Capital, Trade Group Says -- Market Talk

17 juil. 2025, 21:38 UTC

Acquisitions, Fusions, Rachats

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- 2nd Update

17 juil. 2025, 21:22 UTC

Acquisitions, Fusions, Rachats

Update: Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17 juil. 2025, 21:05 UTC

Résultats

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17 juil. 2025, 21:04 UTC

Acquisitions, Fusions, Rachats

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- Update

17 juil. 2025, 21:02 UTC

Acquisitions, Fusions, Rachats

Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17 juil. 2025, 20:59 UTC

Acquisitions, Fusions, Rachats

Basel Medical Group Puts $1B Bitcoin Purchase on Hold

17 juil. 2025, 20:50 UTC

Market Talk
Résultats

Tech, Media & Telecom Roundup: Market Talk

17 juil. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

Comparaison

Variation de prix

Xencor Inc prévision

Objectif de Prix

By TipRanks

196.47% hausse

Prévisions sur 12 Mois

Moyen 26.89 USD  196.47%

Haut 38 USD

Bas 6 USD

Basé sur 11 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

11 ratings

10

Achat

0

Maintien

1

Vente

Score Technique

By Trading Central

7.87 / 10.84Support & Résistance

Court Terme

Strong Bearish Evidence

Moyen Terme

Weak Bearish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

169 / 376Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Xencor Inc

Xencor, Inc. is a clinical-stage biopharmaceutical company that is focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The Company uses its engineering capabilities to enable its understanding of protein structure and interactions to design XmAb technologies and develop candidates with properties. Its antibody design is focused on the segment of antibodies that interact with target antigens. It is focused on the Fc domain, which is the part of an antibody that interacts with various segments of the immune system and controls antibody structure. The Fc domain is constant and interchangeable among antibodies, and its engineered Fc domains are the XmAb technology, which can be readily substituted for natural Fc domains. Its drug candidates include Plamotamab, XmAb717, Vibecotamab, Tidutamab, XmAb841, XmAb104, XmAb306, XmAb104, XmAb564 and XmAb698.